Kazuyo Moro: Building relationships is essential for gaining both speed and opportunities in research.

IF 12.6 1区医学 Q1 IMMUNOLOGY

Journal of Experimental Medicine Pub Date : 2025-03-03 Epub Date: 2024-12-04 DOI:10.1084/jem.20242176

Montserrat Cols

引用次数: 0

Abstract

Professor Kazuyo Moro holds dual appointments as a team leader for the Laboratory for Innate Immune Systems at RIKEN IMS as well as Osaka University Graduate School of Medicine. Her lab conducts multifaceted research on type 2 innate lymphoid cells (ILC2), from ILC2 differentiation, activation, suppression, and transcriptional control mechanisms, as well as basic research and drug discovery. The research from Prof. Moro lab aims to build new models and therapies for related immune diseases such as allergies, fibrosis, and metabolic diseases.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Experimental Medicine 医学-免疫学

CiteScore

26.60

自引率

1.30%

发文量

189

审稿时长

3-8 weeks

期刊介绍： Since its establishment in 1896, the Journal of Experimental Medicine (JEM) has steadfastly pursued the publication of enduring and exceptional studies in medical biology. In an era where numerous publishing groups are introducing specialized journals, we recognize the importance of offering a distinguished platform for studies that seamlessly integrate various disciplines within the pathogenesis field. Our unique editorial system, driven by a commitment to exceptional author service, involves two collaborative groups of editors: professional editors with robust scientific backgrounds and full-time practicing scientists. Each paper undergoes evaluation by at least one editor from both groups before external review. Weekly editorial meetings facilitate comprehensive discussions on papers, incorporating external referee comments, and ensure swift decisions without unnecessary demands for extensive revisions. Encompassing human studies and diverse in vivo experimental models of human disease, our focus within medical biology spans genetics, inflammation, immunity, infectious disease, cancer, vascular biology, metabolic disorders, neuroscience, and stem cell biology. We eagerly welcome reports ranging from atomic-level analyses to clinical interventions that unveil new mechanistic insights.